Iradimed (IRMD) AI Stock Analysis

Compare

155 Followers

Top Page

Iradimed

(NASDAQ:IRMD)

Rating:80Outperform

Price Target:

$67.00

▲(15.18%Upside)

Iradimed's overall stock score is driven by its strong financial performance and optimistic earnings call, reflecting robust growth and strategic positioning in the medical devices market. While technical indicators support positive momentum, valuation concerns with a high P/E ratio and moderate dividend yield suggest careful consideration. Potential risks from international sales and tariff impacts are noted but currently well managed.

Iradimed (IRMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$739.64M

Dividend Yield1.17%

Average Volume (3M)37.39K

Price to Earnings (P/E)37.6

Beta (1Y)0.84

Revenue Growth11.04%

EPS Growth9.84%

CountryUS

Employees160

SectorHealthcare

Sector Strength59

IndustryMedical - Devices

Share Statistics

EPS (TTM)0.42

Shares Outstanding12,715,109

10 Day Avg. Volume45,586

30 Day Avg. Volume37,387

Financial Highlights & Ratios

PEG Ratio14.94

Price to Book (P/B)8.58

Price to Sales (P/S)0.00

P/FCF Ratio55.23

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue2.50

Enterprise Value/Gross Profit12.50

Enterprise Value/Ebitda7.92

Forecast

1Y Price Target

$71.00

Price Target Upside22.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Iradimed Business Overview & Revenue Model

Company DescriptionIradimed Corporation (IRMD) is a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices. The company specializes in developing and commercializing advanced MRI-compatible patient monitoring systems and non-magnetic infusion pumps. These products are designed to meet the unique needs of MRI environments, ensuring patient safety and compliance with strict regulatory standards. Iradimed's solutions are widely used in hospitals and medical facilities around the world, catering to a critical niche in the healthcare sector.

How the Company Makes MoneyIradimed makes money primarily through the sale of its MRI-compatible medical devices, including patient monitoring systems and infusion pumps. The company generates revenue by selling these products directly to hospitals, healthcare facilities, and medical institutions globally. Additionally, Iradimed may earn income from service contracts, maintenance agreements, and spare parts related to their equipment. The company's revenue streams are supported by its strong reputation for quality and compliance, and it may also engage in strategic partnerships or collaborations that enhance its market reach and product offerings.

Iradimed Earnings Call Summary

Earnings Call Date:May 05, 2025

(Q1-2025)

% Change Since: 9.14%|

Next Earnings Date:Jul 31, 2025

Earnings Call Sentiment Neutral

The earnings call reflected a strong performance in key areas such as revenue growth and domestic sales, alongside successful engagement with regulatory agencies. However, challenges such as declining international sales and tariff uncertainties present potential hurdles. The sentiment is balanced with significant achievements and ongoing challenges.

Q1-2025 Updates

Positive Updates

Record-Breaking Revenue

For the first quarter of 2025, IRADIMED Corporation achieved record revenue of $19.5 million, marking an 11% increase over the same period last year.

Strong Earnings Growth

GAAP diluted earnings per share increased 16% from Q1 of 2024, demonstrating strong profitability for the company.

IV Infusion Pump System Growth

The IV Infusion Pump Systems saw a 16% growth to $6 million, reflecting sustained demand.

Disposables Revenue Surge

Revenue from disposables increased by 23% to $4.9 million, indicative of higher pump utilization.

Domestic Sales Success

Domestic sales accounted for 82% of total revenue in Q1 2025, up from 76% in Q1 of 2024, with domestic revenue increasing by 19% to $16 million.

New Facility Progress

The new facility is nearing completion with an expected full operational start by end of July 2025.

Engagement with FDA

Quick response from the FDA on the 510(k) submission for the 3870 MR IV pump, indicating efficient progress.

Negative Updates

International Sales Decline

International sales decreased by 15% to $3.5 million, signaling challenges outside the domestic market.

Research and Development Expense Cut

R&D expenses decreased by 24% to $0.6 million, possibly indicating reduced investment in innovation.

Potential Tariff Impact

Tariff impacts, particularly from Chinese materials, could potentially increase costs, although currently managed well.

Uncertainty in FDA Clearance Timeline

While the FDA has been responsive, there remains uncertainty in the timeline for the 3870 MR IV pump clearance.

Company Guidance

During the IRADIMED Corporation's first-quarter 2025 earnings call, CEO Roger Susi provided guidance for the upcoming quarter and the full year. For Q2 2025, the company expects revenue between $19.7 million and $19.9 million, GAAP diluted earnings per share (EPS) between $0.37 and $0.40, and non-GAAP diluted EPS between $0.41 and $0.44. The full-year 2025 guidance includes projected revenue between $78 million and $82 million, GAAP diluted EPS of $1.55 to $1.65, and non-GAAP diluted EPS of $1.71 to $1.81. The guidance reflects confidence in sustained demand for their products, including the anticipated launch of the new 3870 MR IV pump, expected to contribute to revenue starting in late 2025 and significantly more in 2026. Additionally, IRADIMED remains optimistic despite potential risks associated with tariffs and regulatory challenges, as they continue to monitor and address these issues proactively.

Iradimed Financial Statement Overview

Summary

Iradimed demonstrates strong revenue growth, robust gross profit margins, and efficient operational management. The balance sheet is notably healthy with low debt and impressive ROE, while cash flow is stable despite some capital expenditure fluctuations.

Income Statement

Very Positive

Iradimed has demonstrated robust revenue growth with a 41.0% increase from 2022 to 2023 and a further 14.0% increase in 2024. Gross profit margins have remained strong, averaging around 77% over recent periods. The company maintains healthy EBIT and EBITDA margins, showcasing strong operational efficiency and profitability. However, the net profit margin, while solid, indicates room for further optimization.

Balance Sheet

Very Positive

The balance sheet of Iradimed is very healthy, with a remarkably low debt-to-equity ratio, indicating minimal leverage risk. The equity ratio is strong, reflecting a robust balance of equity to total assets. ROE is impressive, showing efficient use of equity to generate profits. Overall, the company has a solid financial position with low liabilities relative to equity.

Cash Flow

Positive

Iradimed shows a positive cash flow trend, with stable free cash flow generation despite fluctuations in capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion from profits. The free cash flow to net income ratio is consistent, though recent capital expenditures have slightly impacted free cash flow growth.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
75.15M	73.24M	65.56M	53.30M	41.81M	31.72M
	Gross Profit
57.80M	56.35M	50.16M	41.28M	32.05M	23.57M
	EBIT
22.65M	21.96M	20.04M	15.63M	9.82M	-756.09K
	EBITDA
22.77M	22.78M	20.80M	16.30M	11.22M	582.73K
	Net Income Common Stockholders
19.78M	19.23M	17.19M	12.83M	9.33M	1.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
42.78M	52.23M	49.76M	57.96M	62.50M	51.98M
	Total Assets
75.62M	98.33M	92.16M	85.51M	82.88M	71.07M
	Total Debt
2.35M	154.69K	2.04M	2.21M	2.48M	2.72M
	Net Debt
-40.43M	-52.08M	-47.72M	-55.76M	-59.52M	-47.35M
	Total Liabilities
11.28M	11.51M	20.74M	11.84M	10.71M	9.68M
	Stockholders Equity
64.34M	86.82M	71.42M	73.67M	72.17M	61.38M
Cash Flow		Free Cash Flow
14.00M	17.62M	5.46M	8.17M	10.52M	5.18M
	Operating Cash Flow
26.03M	25.62M	13.47M	10.04M	11.26M	5.82M
	Investing Cash Flow
-12.26M	-8.82M	-8.01M	-1.37M	648.24K	246.97K
	Financing Cash Flow
-8.57M	-14.34M	-13.66M	-12.71M	24.43K	522.48K

Iradimed Technical Analysis

Technical Analysis Sentiment

Positive

Last Price58.17

Price Trends

50DMA

53.82

Positive

100DMA

54.67

Positive

200DMA

53.15

Positive

Market Momentum

MACD

1.87

Negative

RSI

56.48

Neutral

STOCH

56.32

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Positive. The current price of 58.17 is above the 20-day moving average (MA) of 56.78, above the 50-day MA of 53.82, and above the 200-day MA of 53.15, indicating a bullish trend. The MACD of 1.87 indicates Negative momentum. The RSI at 56.48 is Neutral, neither overbought nor oversold. The STOCH value of 56.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRMD.

Iradimed Risk Analysis

Iradimed disclosed 36 risk factors in its most recent earnings report. Iradimed reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 2 New Risks

The constant growth and development of technology, including the increased use of Artificial Intelligence, presents risks and challenges to our operations that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm of our business. Q4, 2024

A cyber security incident or failure to protect our information technology infrastructure could be disruptive to our business, compromise confidential data, cause reputation harm, adversely affect our business and operating results, subject us to litigation and federal and state governmental inquiries. Q4, 2024

Iradimed Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	80 Outperform	$739.64M	37.61	23.81%	1.17%	11.04%	9.84%
SIBN	72 Outperform	$742.34M	―	-15.96%	―	22.60%	41.26%
CBLL	59 Neutral	$624.19M	―	26.25%	―	―	―
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
AVNS	52 Neutral	$559.55M	45.80	-36.78%	―	1.34%	-530.36%
BVS	47 Neutral	$543.80M	―	-19.79%	―	8.60%	-42.76%
RXST	44 Neutral	$577.45M	―	-11.98%	―	46.69%	46.68%

* Healthcare Sector Average

Performance Comparison

IRMD

Iradimed

58.17

15.66

36.84%

AVNS

Avanos Medical

12.10

-6.84

-36.11%

SIBN

SI-Bone

17.42

4.92

39.36%

BVS

Bioventus

6.62

0.68

11.45%

RXST

RxSight

14.21

-41.90

-74.67%

CBLL

Ceribell, Inc.

17.27

-8.23

-32.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.